Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegamotecan
- Development stage
- Phase 2
- Lead developer
- Enzon Pharmaceuticals
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Pegamotecan is a pegylated derivative of camptothecin and acts as a DNA topoisomerase I inhibitor. The pegylation (attachment of polyethylene glycol) increases its water solubility, prolongs circulating half-life, improves tolerability, and allows for passive tumor accumulation. It was developed by Enzon Pharmaceuticals for the treatment of various cancers including gastric cancer, soft tissue sarcoma, and gastroesophageal cancer. Clinical trials showed some activity in advanced gastric and gastroesophageal adenocarcinoma with manageable toxicity; however, development was discontinued after phase II studies due to strategic considerations regarding investment return versus required resources[1][2][3][5].
- Brand names
- Prothecan
- Other names
- camptothecin macrogolpolyethylene glycol camptothecin
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on pegamotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegamotecan.